Oncology News

Bristol Myers Squibb in consultation with the FDA voluntarily withdrew the indication for nivolumab as monotherapy for patients with hepatocellular carcinoma previously treated with sorafenib.

The combination of cabozantinib and atezolizumab prolonged PFS compared with sorafenib among patients with previously untreated advanced hepatocellular carcinoma, according to topline data released by one of the agent’s manufacturers.

Treatment with hepatic arterial infusion chemotherapy in combination with sintilimab allowed for surgical resection and produced survival rates similar to lesser advanced hepatocellular carcinoma, according to a presenter at The International Liver Congress.

Transforming growth factor beta mutation biomarkers may help identify patients at high risk for cancer of the liver, pancreas and gastrointestinal system, according to data published in Gastroenterology.

Patients with cirrhosis prioritize early-detection over factors like convenience when it comes to hepatocellular carcinoma surveillance, according to study results.

In an exclusive interview with Healio Gastroenterology, Richard Finn, MD, discussed the results from a recent study of patients with hepatocellular carcinoma treated with combination therapy comprising atezolizumab, an immunotherapy drug and monoclonal antibody, and bevacizumab, another monoclonal antibody against the vascular endothelial growth factor (VEGF).

Despite having better liver function at diagnosis, Black patients with hepatitis C virus tended to have more aggressive hepatocellular carcinoma tumors compared with other racial groups, according to a study published in Cancer.

The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.